NCT02994979

Brief Summary

Delirium is an acute confusion that occurs in one third of hospitalized older adults. As compared to those without delirium, hospitalized patients with delirium have longer hospital stays, higher mortality, and increased risk of nursing home utilization. Substantial attention has been paid to developing, testing, and disseminating interventions to prevent delirium in the hospital but, to date, not in the nursing home setting. In a previous study we used known information on delirium risk factors to develop an intervention that can be delivered at onset of acute illness in nursing home patients. The current study is designed to test the effect of this intervention in a single-site clinical trial. Objectives: 1) to determine, as compared to control, the effect of a multicomponent intervention targeting delirium risk factors on delirium frequency, delirium severity, cognitive and physical function decline, and hospitalization in nursing home patients with acute illness, and 2) to identify features of the intervention associated with occurrence of delirium and other outcomes. Approach: We will screen nursing home patients on 17 long-term care units at a large, urban nursing home who experience onset of a change in condition according to established criteria, and enroll and assign them to intervention or control in a 1:1 ratio. Those assigned to intervention will receive daily visits from an Elder Life Specialist, a mobile Certified Nursing Assistant trained to provide services to counter risks for delirium, including dehydration, immobility, cognitive impairment, undernutrition, and sleep problems, for the duration of the acute illness and for 1 week following. Patients assigned to control will receive usual care from the unit-based nurses and the patient's primary team. Delirium will be assessed 5 days a week by a research assistant. Cognitive and physical function decline and hospital transfer will be ascertained during a 1 month follow-up period. We will compare outcomes between intervention and control, as well as examine associations between outcomes and intervention features such as number and duration of visits.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
219

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Nov 2016

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2016

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

December 9, 2016

Completed
7 days until next milestone

First Posted

Study publicly available on registry

December 16, 2016

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 21, 2018

Completed
7 days until next milestone

Study Completion

Last participant's last visit for all outcomes

August 28, 2018

Completed
1.2 years until next milestone

Results Posted

Study results publicly available

November 4, 2019

Completed
Last Updated

November 4, 2019

Status Verified

October 1, 2019

Enrollment Period

1.8 years

First QC Date

December 9, 2016

Results QC Date

September 11, 2019

Last Update Submit

October 15, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Number of Participants With Delirium

    Confusion Assessment Method (CAM)

    During acute condition, up to 3 weeks

Secondary Outcomes (3)

  • Physical Function at 1 Month

    Baseline and 1 month

  • Cognitive Function at 1 Month

    Baseline and 1 month

  • Number of Participants Admitted to Hospital

    Up to 1 month

Study Arms (2)

Delirium-prevention group

EXPERIMENTAL

Multicomponent delirium prevention intervention led by a Certified Nursing Assistant (CNA) adapted for the long-term care setting from the Hospital Elder Life Program.

Other: Delirium-prevention

Usual care group

SHAM COMPARATOR

Usual care plus a sham visit from the intervention CNA

Other: Sham comparator

Interventions

Patients will be seen by an intervention CNA at least once daily 7 days a week. The CNA will be English/Spanish bilingual and will provide intervention components guided by structured protocols and a daily visit form. A typical visit lasts 30 minutes and begins with an introduction and orientation activity followed by provision of water, a reminiscence activity or game, a physical exercise, and a snack and second cup of water. Patients may also receive a relaxation visit at night and given a warm drink, a hand or foot massage, and quiet music. Daily visits will last for the duration of the illness and 7 days following the illness end. Illness end is defined as the last day of illness treatment (e.g., last day of antibiotics) or monitoring (e.g., last day on nursing "24-hour report"). During weekly intervention staff meetings patients will be discussed with the primary medical and nursing team. The planned intervention group sample size results in a case load of 4-8 patients.

Also known as: HELP-LTC
Delirium-prevention group

Usual care plus sham visits by CNA

Usual care group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Long-term care nursing home resident at The New Jewish Home
  • Acute change in condition or just returned from the hospital
  • Assent to participate in study

You may not qualify if:

  • Discharge or death expected before 2 months
  • Nonverbal or unable to follow simple commands

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The New Jewish Home

New York, New York, 10025, United States

Location

MeSH Terms

Conditions

Delirium

Condition Hierarchy (Ancestors)

ConfusionNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and SymptomsNeurocognitive DisordersMental Disorders

Results Point of Contact

Title
Dr. Kenneth Boockvar
Organization
The New Jewish Home

Study Officials

  • Kenneth Boockvar, MD

    Mount Sinai School of Medicine; The New Jewish Home

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 9, 2016

First Posted

December 16, 2016

Study Start

November 1, 2016

Primary Completion

August 21, 2018

Study Completion

August 28, 2018

Last Updated

November 4, 2019

Results First Posted

November 4, 2019

Record last verified: 2019-10

Locations